Element Biosciences, where courage meets possibility

We’re passionate about building new and differentiated technologies that will disrupt the genomics industry. We pursue rigorous science that supports data-driven decisions in ever-evolving markets. We take risks to challenge the status quo. We celebrate our successes and learn from our failures. We’re committed to empowering customers with unprecedented freedom to study biology.

​

We’re excited to announce Element Biosciences raises $30M, an extension to the previously announced $80M Series B financing. The combined funds will continue to support our product development and hiring activities toward bringing a new DNA sequencing platform to market.

Every element of a DNA sequencer – reimagined.

Genetic sequencing has become an increasingly powerful tool to understand biology and improve human life. Element Biosciences is creating a brand-new DNA sequencing platform to meet diverse and ever-changing needs in this dynamic market.

Element Biosciences Raises $80M in Series B Financing to Accelerate Development of a New DNA Sequencing Platform

SAN DIEGO, Calif. — Element Biosciences today announced the close of a Series B financing round of $80.3 million, with participation from new investors Fidelity Management & Research Company and JS Capital LLC, as well as existing investors Foresite Capital and Venrock. To date, the company has raised a total of more than $100 million. Proceeds from the financing will be used to accelerate the development of high-quality, low-cost, and easy-to-use genomic sequencing solutions.

Careers

Our team of professionals is here to inspire and impress the industry with unique ideas and abilities - and to welcome new ones.